ArticleCancers2021
NLRP7 Promotes Choriocarcinoma Growth and Progression through the Establishment of an Immunosuppressive Microenvironment.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- Artificial intelligence-driven high-content imaging decodes for NLRP7-mutant recurrent hydatidiform moles.iScience · 2026Article
- Inflammasomes meet organoids and artificial intelligence: unraveling the complexity of gynecological inflammation.Frontiers in immunology · 2026Review
- Trophoblast invasion biology: from normal implantation to accreta spectrum and choriocarcinoma.Vascular biology (Bristol, England) · 2026Review
- NLRPs and tumor: research progress from molecular mechanisms to clinical applications.Oncogene · 2026Review
- Modulation of the PGRMC1/NLRP7/HLA-C axis by autophagy is linked to both spontaneous preterm birth and gestational choriocarcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Gestational trophoblastic disease: understanding the molecular mechanisms of placental tumours.Disease models & mechanisms · 2025Review
- In Vivo Quantitative Assessment of Gestational Choriocarcinoma Development and Progression Using Luminescent Trophoblast Cells.Methods in molecular biology (Clifton, N.J.) · 2024Article
- NLRP7 Enhances Choriocarcinoma Cell Survival and Camouflage in an Inflammasome Independent Pathway.Cells · 2023Article
- Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases.Medical oncology (Northwood, London, England) · 2023Review
- Identification of a pyroptosis-based model for predicting clinical outcomes from immunotherapy in patients with metastatic melanoma.Cancer medicine · 2023Article
- Article
- Role of NLRP7 in Normal and Malignant Trophoblast Cells.Biomedicines · 2022Review
- A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.Frontiers in oncology · 2022Article
- Case Report: First-Line Immune Checkpoint Inhibitor Plus Chemotherapy for Oral Metastasis in a Patient with Ultra High-Risk Gestational Choriocarcinoma.Cancer management and research · 2022Article
- Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease.Biomedicines · 2021Article
- Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 5 countries.
Deborah ReynaudInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.ORCID 0000-0002-6968-4215
Roland Abi NahedInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.ORCID 0000-0002-8767-6462
Nicolas LemaitreInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.
Pierre-Adrien BolzeDepartment of Gynecological Surgery and Oncology, Obstetrics, French Reference Center for Gestational Trophoblastic Diseases, University Hospital Lyon Sud, University of Lyon 1, 69000 Lyon, France.ORCID 0000-0002-4988-9723
Wael TraboulsiLaboratory for Immuno-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 2005, USA.
Frederic SergentInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.
Christophe BattailInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.ORCID 0000-0001-6849-7824
Odile FilholInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.ORCID 0000-0003-1964-7958
Vincent SapinGenetics, Reproduction and Development (GReD) Laboratory, CNRS UMR 6293, Inserm U1103, Translational Approach to Epithelial Injury and Repair Team, Clermont Auvergne University, 63000 Clermont-Ferrand, France.ORCID 0000-0002-7452-315X
Houssine BoufettalObstetrics and Gynecology Department, Ibn Rochd University Hospital, Hassan 2 University, Faculty of Medicine and Pharmacy, 20360 Casablanca, Morocco.
Pascale HoffmannInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.
Touria AboussaouiraObstetrics and Gynecology Department, Ibn Rochd University Hospital, Hassan 2 University, Faculty of Medicine and Pharmacy, 20360 Casablanca, Morocco.
Padma MurthiDepartment of Pharmacology, Monash Biomedicine Discovery Institute, Monash, Clayton, VIC 3168, Australia.ORCID 0000-0003-2535-5134
Rima SlimDepartments of Human Genetics and Obstetrics and Gynecology, McGill University Health Centre Research Institute, Montréal, QC H4A 3J1, Canada.ORCID 0000-0002-4060-2159
Mohamed BenharougaInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.ORCID 0000-0002-5472-6806
Nadia AlfaidyInstitut National de la Santé et de la Recherche Médicale, Inserm U1292, Université Grenoble-Alpes, 38000 Grenoble, France.ORCID 0000-0002-0718-2447
Inserm · FRUniversity of Hassan II Casablanca · MACentre National de la Recherche Scientifique · FRGeorgetown University · USMcGill University Health Centre · CAThe University of Melbourne · AUUniversité Claude Bernard Lyon 1 · FR
Funding
Agence Nationale de la Recherche 17-EURE-0003Agence Nationale de la Recherche ANR-17-EURE-000FRM SPF20150934074LIGUE SAVOIE 2017
Abstract
The inflammatory gene
Indexed as
choriocarcinomahydatidiform molematernal immune toleranceNLRP7orthotopic model of choriocarcinomatumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.